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ABSTRACT
Background: Non-alcoholic fatty liver disease
(NAFLD) is the most common cause of chronic liver
disease worldwide, with prevalence above 30% in
many adult populations. Strongly associated with
obesity, weight loss through diet and physical activity
is the mainstay of its management. Weight loss can be
difficult to achieve and maintain however, and
uncertainty exists as to which lifestyle changes are
most effective.
Objective: The aim of this work was to systematically
evaluate randomised controlled trials assessing diet,
exercise or combination interventions aimed at
reducing steatosis or markers of NAFLD activity.
Design: Medline, Scopus and Cochrane databases
were searched from 1 January 1980 through to 31 July
2016, for intervention trials assessing the effects of
diet, weight loss, exercise or any combination thereof,
on NAFLD disease markers in human adults. Risk of
publication bias and study quality was assessed using
the American Dietetic Association Quality Criteria
Checklist.
Results: From a total of 1710 identified records, 24
articles met the inclusion and exclusion criteria; 6
assessed weight loss using dietary restriction, 10
assessed exercise and 8 were combination
interventions. While all of the trials demonstrated
significant reduction in steatosis and/or markers of
NAFLD activity, combination interventions appear to be
the most effective at improving NAFLD. Results
suggest that 5–10% weight loss using a modestly
hypocaloric diet of 500 kcal less per day than
calculated energy requirement, in combination with
30–60 min exercise on 3–5 days per week should be
recommended.
Conclusions: We conclude this amount of weight
loss is achievable in the trial setting but is challenging
in the clinical environment. High-intensity,
multidisciplinary intervention in specialist clinics is
likely to be required in order to manage NAFLD by
lifestyle modification alone. This systematic review
protocol was registered prospectively at PROSPERO as
CRD42016032764.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is
a spectrum of liver pathology, strongly asso-
ciated with obesity and diabetes. Described
as the hepatic component of metabolic syn-
drome, NAFLD is now the most common
cause of chronic liver disease worldwide.1
Prevalence estimates vary depending on
population and ethnicity, but current data
suggest prevalence may be as high as 45% of
the adult population in many countries.2
While the majority of people affected have
simple steatosis, which confers a relatively
low risk, up to 50% of patients with NAFLD
will develop complications including steato-
hepatitis, ﬁbrosis, cirrhosis and end-stage
liver failure or hepatocellular carcinoma.3
Determining the precise incidence and
prevalence of NAFLD is problematic as
NAFLD is generally an incidental ﬁnding in
the clinical setting, and the lack of a precise
and inexpensive diagnostic tool makes popu-
lation studies on a large scale difﬁcult.1 A
diagnosis of NAFLD can only be made in the
absence of signiﬁcant ethanol intake (<20 g/
day in men and 10 g/day in women). In add-
ition, the exclusion of other causes of stea-
tosis, including; hepatitis C, medication,
malnutrition, rapid weight loss and inﬂam-
matory bowel disease, is also required.4–6
Importantly, evidence suggests it is possible
to delay or even reverse disease progression
in the earlier stages of NAFLD, and many
therapeutic agents and nutritional supple-
ments have been studied to this end, with
some showing some limited promise in
phase II and III clinical trials.7 However, cur-
rently there is no speciﬁc pharmaceutical
agent for the treatment of NAFLD, and life-
style change aimed at weight loss remains the
mainstay of clinical management guide-
lines.4–6
Weight loss and increased physical activity
are known to be associated with improve-
ments in other components of metabolic syn-
drome, possibly by reducing the enhanced
inﬂammatory state associated with the condi-
tion.8 9 While there is general consensus that
many types of lifestyle interventions should
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be effective in reducing steatosis and improving histo-
logical markers of disease progression, comparison
proves difﬁcult because of the diversity of intervention
protocols and NAFLD diagnostic and outcome criteria
used in trials.10 Recent meta-analyses examining exercise
interventions suggest positive effects on reduction in
alanine aminotransferase (ALT) levels and intrahepatic
fat, although the clinical signiﬁcance of reported stand-
ard mean differences can be difﬁcult to interpret.11 12
These reviews highlight the considerable heterogeneity
in duration and types of exercise intervention employed.
While they both conclude a beneﬁt to exercise interven-
tion, some low-quality trials were included and questions
about inclusion and exclusion criteria, grouping of
studies and the role of diet and weight loss remain.
In this context, the aim of this review was to systematic-
ally evaluate the existing randomised controlled trials
(RCTs) assessing the effects of interventions involving
diet, weight loss, exercise or any combination thereof,
on biochemical, radiological or histological markers of
NAFLD in adults. It was hypothesised that weight loss
and exercise interventions would be effective, and that
combination interventions would be more effective than
weight loss or exercise alone.
METHODS
Methods of the analysis and eligibility criteria were speci-
ﬁed prior to the literature search and documented in a
protocol registered with Prospero (CRD42016032764).
The review was conducted by SK according to Preferred
Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines13 including inde-
pendent execution of search strategy and bias assess-
ment, completed by JS; third-party adjudication was
done by JBM. The PubMed, Scopus and the Cochrane
databases were searched from 1 January 1980 to 31 July
2016. The search terms were ‘NAFLD and exercise’,
‘NAFLD and weight loss’ and ‘NAFLD and diet/diet,
reducing’ for PubMed and Scopus, and ‘NAFLD’ for the
Cochrane database. The searches were limited to clinical
trials, human studies, English language and journal arti-
cles where possible.
RCTs in human adults of any gender/ethnicity with a
diagnosis of NAFLD, non-alcoholic steatohepatitis
(NASH), ﬁbrosis or NAFLD-based cirrhosis made on
validated biochemical, radiological or histological evi-
dence were included; other causes of fatty liver disease
were excluded. Papers excluded from this review were:
non-human studies, letters/case reports, studies relating
to children, articles not reporting primary outcomes of
interest or primary data reporting, and trials using
non-invasive methods that have not been validated.
Included trials had to have measured as primary out-
comes either: changes in biochemical, radiological or
histological markers of NAFLD in response to a diet,
weight loss or exercise (or combination of these) inter-
vention. The validity of eligible RCTs was assessed
using the American Dietetic Association (ADA) quality
assessment tool.14
Information was recorded from each included trial,
speciﬁcally: (1) the aim of the intervention; (2) the
method of recruiting participants; (3) the inclusion and
exclusion criteria for the study; (4) whether or not
informed consent was obtained; (5) whether or not
ethics approval had been sought and granted; (6) any
funding sources; (7) the statistical methods used to
analyse the data; (8) methods of randomisation;
methods of allocation concealment; blinding of partici-
pants and personnel where appropriate; blinding of the
outcome assessment; (9) incomplete outcome data
reporting; any selective reporting and other sources of
bias as detailed in the Cochrane handbook.15
In addition, further information recorded from each
trial included: the principal and secondary outcome
measures as identiﬁed by the authors; the methods of
assessing outcome measures; the validity and reliability
of the outcome measures; the methods of follow-up for
non-respondents; the timing of the outcome assessment
and any adverse events. The primary measures of the
treatment effects were relative reduction in markers of
NAFLD compared with controls. These included degree
of steatosis on imaging, levels of biochemical markers of
NAFLD, histological assessment of NAFLD activity score
(NAS) and change in biochemical indices aimed at
assessing degree of NAFLD, for example, the fatty liver
index (FLI) or the visceral adiposity index (VAI).
RESULTS
Search results
The identiﬁcation and selection of eligible studies
included in this review are illustrated in ﬁgure 1.
Database searches returned 1979 citations with 269
included in more than one search. Following removal of
duplicates, 1710 citations remained. These publications
were screened for eligibility by reading the abstracts and
those not meeting the eligibility criteria were excluded.
Papers excluded were either animal studies, drug/sup-
plementation trials, review papers, trials done in chil-
dren and trials that were not randomised and/or
controlled, trials not assessing NAFLD markers as a
primary outcome and non-English articles. This resulted
in 43 trials which, based on reading the abstracts, met
the inclusion criteria for this review. The papers report-
ing these trials were then read in full. Following this, a
further 19 trials were excluded, for the following
reasons: ﬁve were not randomised; three had no control
or cointervention group; ﬁve did not require a diagnosis
of NAFLD as an inclusion requirement; one included
subjects with hepatitis C so did not meet the exclusion
criteria. Two were retrospective studies and three evalu-
ated a primary outcome that was not related to NAFLD.
Five trials did not specify NAFLD as an inclusion criter-
ion, but did assess and report change in NAFLD as a
main outcome and were included.16–20
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Trial characteristics
Overall, 2322 individuals participated in a total of 24
trials with durations ranging from 2 weeks to 1 year. Of
the 24 trials that met the inclusion and exclusion cri-
teria, 620–25 assessed weight loss through dietary modiﬁ-
cation (table 1), 1016–19 26–31 assessed exercise (table 2),
and 832–39 investigated the effects of a combination of
diet and exercise (table 3).
The protocols for the interventions were diverse. The
trials assessing dietary intervention alone were all hypo-
caloric but reductions in food intake ranged from a
mild decrease of 200 kcal/day24 to a very low calorie diet
(VLCD) with a total intake of 450 kcal/day.20 Dietary
compositions were different for each of the 6 interven-
tions. The majority of exercise interventions were
various forms of aerobic exercise such as cycling ergom-
eter16 18 or walking at high intensity;19 however three
studies considered the effects of differing resistance
exercise regimes alone27 29 30 while the protocol for one
involved counselling alone, aimed at increasing physical
activity.26 Similarly, there was considerable heterogeneity
among the combination interventions.
Inclusion and exclusion criteria also varied; of the 24
trials, 10 speciﬁed overweight or obesity as a require-
ment.16 18–20 22 28 34–36 39 Diabetes status was sometimes an
inclusion criterion16 17 but more often a reason for exclu-
sion.18 20 22 24 28 29 32 The majority of trials included parti-
cipants of both genders (age 18–75), with the percentage
participation of each sex varying across the studies,
although a minority included exclusively male36 or
female35 subjects. Five interventions involving exercise also
excluded those who were physically unable to complete
the protocol.17 29 30 32 34 All but one of the interventions
assessing exercise without dietary modiﬁcation required
participants to have been sedentary prior to the interven-
tion.30 The trials took place in a wide range of geographical
locations; however, only four studies speciﬁed ethnicity as
an inclusion/exclusion criterion.16 17 20 33
By our review criteria, outcome measures always
included changes in hepatic markers. However, asso-
ciated or secondary outcomes varied markedly between
studies, with some assessing only liver outcomes while
others also reported data relating to weight, body mass
index, glucose metabolism, cardiovascular ﬁtness and
other markers linked with NAFLD. The methods of diag-
nosing and measuring change in NAFLD were also het-
erogeneous, the most common being MRI/magnetic
resonance spectroscopy (MRS) in eight of the
studies;16 18 19 23 27 28 33 38 three trials required a
biopsy,21 34 37 ﬁve assessed NAFLD using ultra-
sound,20 29 31 32 35 ﬁve were based on liver biochemis-
try,17 22 26 36 39 two on ultrasound and liver
biochemistry24 31 and one on the Asian Working Party
Guidelines for the diagnosis of NAFLD.30 40 One paper
excluded those with simple steatosis and assessed only
participants with steatohepatitis.34
Figure 1 Flow diagram showing
identification and selection of
relevant studies for inclusion in
this systematic review.
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Table 1 Trials evaluating dietary intervention alone on NAFLD-related outcomes
Author
(year);
country Intervention
Age range;
sample size
(% male)
Study
duration Outcome measures
Changes to outcome measures
postintervention
Yamamoto
(2007);21
Japan
Low calorie (126 kJ/kg/d), low fat (20%),
low iron (≤6 mg/d) and 1.1–1.2 g/kg/d protein
37–74;
27 (52%)
6 months Primary: AST, ALT
Other: WT, BMI, TG, TC, GLC,
Iron, FER, TS
Primary:
↓ AST*
↓ ALT*
↓ WT* (4.8%) and ↓ BMI*
Lin (2009);20
Taiwan
VLCD of 450 kcal/day or 800 kcal/day 18–65;
132 (34%)
12 weeks Primary: NAFLD (ultrasound)
resolution and improvement
Other: WT, BMI, WC, FM, GLC,
BP, TG
95 completed trial;
NAFLD resolved in 5 cases (450 kcal
group) and 10 cases (800 kcal group)
NAFLD improved in 17 cases
(450 kcal group) and 21 cases
(800 kcal group)
↓ WT* 9.14% (450 kcal/day), ↓ 8.98%
(800 kcal/day), and ↓ BMI*
De Luis
(2010);22
Spain
Low fat, low calorie (1500 kcal/day, 27% fat/
53% CHO) or low CHO, low calorie diet (1507
kcal/day, 38% CHO/36% fat)
29–64;
162 (29%)
3 months Primary: AST, ALT
Other: WT, BMI, BP, TC, HDL,
LDL, TG, FM, WC, WHR, GLC,
INS, HOMA
Low fat (NAFLD):
↓AST*
↓ALT*
↓WT* (3.9%) and ↓ BMI*
Low-CHO diet (NAFLD):
↓AST*
↓ALT*
↓WT* (4.9%) and ↓ BMI*
Browning
(2011);23
USA
Low CHO (<20 g/d) or low calorie (1200–
1500 kcal/d)
33–57;
18 (27%)
2 weeks Primary: IHTG (MRS), AST,
ALT
Other: WT, BMI, TC, TG, GLC
↓ IHTG* 28% (low cal), 55% (low
CHO);
↓ AST*; ↑ ALT§ ; ↓ BMI*
↓ WT* (4.2% low cal and 4.7% low
CHO) and ↓ BMI*
Kani (2014);24
Iran
Calorie restriction (200–500 kcal/day; 55%
CHO, 15% protein, 30% fat)
Calorie restriction, low CHO (45% CHO, 20%
protein, 35% fat)
Calorie restriction, low CHO + 30 g soy protein
43–52;
45 (46%)
8 weeks Primary: AST, ALT
Other: WT, BMI, INS, TG, TC,
HDL, LDL, ALP, FIB, MDA
↓ AST* and ALT* in all groups;
greatest reduction seen in the soy
group.
All diets saw ↓ WT*: 3.9%, 4.2%,
4.7%, respectively and ↓ BMI*
Razavi Zade
(2016);25
Iran
Calorie restriction (350–700 kcal) or
Calorie restriction and DASH diet (rich in fruit,
veg, whole grains and low fat dairy; low in
saturated fats, cholesterol and sugar)
25–75;
60 (50%)
8 weeks Primary: Steatosis grade
(ultrasound), AST, ALT
Other: WT, VLDL, LDL, HDL
Steatosis grade improved on both
diets; more cases improved on DASH
(80% vs 43%)*
↓ AST* ↓ ALT* with DASH not low cal
↓ WT* ( 3.0% low cal and 4.6%
DASH)
*Statistically significant; §No statistical difference.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index (kg/m2); BP, blood pressure; CHO, carbohydrate; DASH, dietary
approaches to stop hypertension; FER, ferritin; FIB, serum fibrinogen; FM, fat mass; GLC, glucose; HDL, high-density lipoprotein; HOMA, Homeostasis Model Assessment; IHTG, intrahepatic
triglyceride; INS, insulin; LDL, low-density lipoprotein; MDA, malondialdehyde; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; NMR, nuclear magnetic
resonance; TC, total cholesterol; TG, triglyceride; TS, transferrin saturation; VLCD, very low calorie diet; VLDL, very low density lipoprotein; WC, waist circumference; WHR = waist:hip ratio; WT,
weight.
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Table 2 Trials evaluating exercise intervention alone on NAFLD-related outcomes
Author (year);
country Intervention
Age range;
sample size
(% male)
Study
duration Outcome measures
Changes to outcome measures
postintervention
Johnson
(2009);18
Australia
Cycle ergometer 30–45 min 3×/week, increasing from
50–70% pretraining VO2 max
43–51;
23 (65%)
4 weeks Primary: IHTG, SI, ALT
Other: WT, BMI, Cholesterol,
IMTG, SAT, VAT
↓ IHTG* 1.76%
No significant change SI, ALT, WT,
BMI
↓ VAT*
St George
(2009);26
Australia
Counselling sessions; low-intensity: 3 fortnightly
consultations; moderate-intensity: 2 groups received 6
fortnightly consultation, with 1 group receiving additional
telephone support
35–60;
141 (61%)
3 months Primary: ALT, AST
Other: WT, BMI, LDL, HDL,
GLC, TC, TG, GGT, physical
activity
↓ ALT*, and ↓ AST* in all groups,
greatest seen in moderate-intensity
intervention
↓ WT* and ↓ BMI*, greatest in
moderate-intensity intervention
Hallsworth
(2011);27
UK
Resistance exercise 45–60 min, 3×/week 33–72;
21 (NS)
8 weeks Primary: IHTG (MRS), ALT
Other: WT, BMI, WC, HC,
WHR, TC, TG, HbA1C, VAT,
SAT, FM, GLC, INS, HOMA-IR
↓ IHTG* 13%; 3 participants moved
from clinical NAFLD to normal (<5%
IHTG)
No change ALT, WT, BMI
Sullivan
(2012);28
USA
Brisk walk 30–60 min, 5×/week 44–51;
18 (38%)
16 weeks Primary: IHTG (MRS), ALT
Other: WT, BM, FM, FFM, VO2
peak, TC, HDL, LDL, TG,
FFA, VLDL
↓IHTG* 10.3% , ↓ ALT*
No change WT
Bacchi
(2013);16
Italy
Aerobic exercise (AER) at 60% VO2 max, 60 min
3×/week or, resistance exercises (RES) 60 min, 3×/week
54–58;
31 (70%)
4 months Primary: IHTG (MRI), ALT,
AST
Other: BMI, HbA1c, GGT, TC,
LDL, HDL, TG, FFM, IATG,
SAT
↓ IHTG* ∼35% in both groups;
hepatic steatosis resolved in 3 AER
and 4 of RES participants
↓ BMI* in both groups
No change ALT, AST
Zelber-Sagi
(2014);29
Israel
Resistance training (RT) 40 min 3×/week or, stretching
exercises 3×/week
35–57;
82 (53%)
3 months Primary: HRI score
(ultrasound), ALT, AST
Other: WT, BMI, BP, GLC,
INS, HOMA, TC, TG, HbA1C,
HDL, LDL, GGT, FER
↓ HRI score* 11% in RT group
↓ WT* and ↓ BMI* compared with
stretching
No change ALT, AST
Keating
(2015);19
Australia
Cycling ergometer and walking at either high intensity/low
volume, 45 min 3×/week (HI/LO); low intensity/high
volume, 60 min 4×/week (LO/HI); or low intensity/low
volume, 45 min 3×/week (LO/LO)
25–59;
48 (35%)
8 weeks Primary: IHTG (MRS), ALT,
AST, SI, WT, BMI
Other: WT, BMI, BP, WC, VO2
max, TG, TC, HDL, LDL, FFA,
INS, GLC, VAT
↓ IHTG* 2.4% (HI:LO), 2.6% (LO:HI),
0.8% (LO:LO)
↓ WT* 1.3% (HI:LO), 1.5% (LO:HI);
↓BMI*
No change ALT, AST, SI
Balducci
(2015);17
Italy
Low-intensity resistance and aerobic exercise 2×/week or;
high-intensity resistance and aerobic exercise 2× /week
Age NS;
606 (58%)
12 months Primary: AST, ALT, FLI
Other: BMI, VAI, GGT, TG,
WC, HOMA-IR, HbA1c
↑ AST*, ↑ ALT*, in exercise and
control groups
↓ FLI*, ↓BMI*, ↓VAI* in exercise
group*
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Dietary interventions
Six trials assessing the effects of dietary intervention on
NAFLD were identiﬁed from: Japan,21 Taiwan,20 Spain,22
USA23 and Iran.24 25 Interventions were heterogeneous
(table 1) and ranged in duration from 2 weeks to
6 months. Notably ﬁve of the six dietary interventions
reported liver enzymes and all saw reductions in these
after intervention. All measured a weight loss from
dietary changes, with most achieving 3.0–4.9%, with the
exception of the VLCD trial carried out by Lin et al20
where participants only consumed 450 kcal/day or
800 kcal/day. This intervention saw larger weight losses
of 9.14% and 8.98%, respectively; with 5 and 10 cases of
NAFLD being completely resolved, as assessed by ultra-
sound. Three of the interventions measured NAFLD
severity by ultrasound or nuclear magnetic resonance,
and only Lin et al20 saw cases resolved; whereas a more
moderate calorie restriction diet carried out by
Browning et al23 saw NAFLD improvement with a 28%
intrahepatic triglyceride (IHTG) reduction; and Razavi
et al25 using a calorie-restricted, dietary approaches to
stop hypertension (DASH) diet resulted in 10 partici-
pants moving from grade III to II NAFLD and 20 from
grade II to I, as assessed by MRS.
Exercise interventions
Ten RCTs assessing the effects of exercise on NAFLD
were identiﬁed from: Australia,18 19 26 UK,27 31 USA,28
Italy,16 17 Israel29 and Japan.30 Interventions ranged from
4 weeks to 12 months (table 2). Eight trials examined the
effects of aerobic exercise, in comparison to a more sed-
entary lifestyle with only standard care implemented,
resulted in improvements in NAFLD17 19 26–28 30 31 as
measured by reduced levels of hepatic enzymes ALT and
aspartate aminotransferase (AST). Six of the 10 interven-
tions also measured and reported percentage change in
IHTG content by either proton MRS (H-MRS)19 27 28 31
or MRI.16 18 This ranged from 1.76–48%, with the smal-
lest percentage change being associated with the shortest
duration intervention of 4 weeks,18 and the largest
change being a trial of longer duration at 4 months.31
The interventions carried out by Bacchi et al16 and
Cuthbertson et al31 were both 4 months (16 weeks) in
duration with cohorts of similar age and both supervised
in exercise achieving 48% and 35% reduction in %
IHTG, respectively. However the Bacchi trial deﬁned all
three exercise sessions per week as supervised, and the
Cuthbertson trial saw participants attend the gym weekly
and were monitored through the wellness system which
tracked exercise within designated facilities; so the results
could be indicative of the beneﬁcial role of direct supervi-
sion, in the form of personal trainers.
Combination interventions
Eight trials that assessed the effects of a combination of
dietary and exercise interventions were identiﬁed from:
Taiwan,32 Germany,33 USA,34 37 Mexico,35 Hong Kong38
and Spain39 (table 3). These trials ranged in durations
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Table 3 Trials evaluating combination of exercise and dietary intervention on NAFLD outcomes
Author (year); country Intervention
Age
range;
sample
size
(% male)
Study
duration Outcome measures
Changes to outcome measures
postintervention
Chen (2008);32
Taiwan
Hypocaloric diet 1200–1500 kcal/day and 1 hour
2×/week on stationary cycle (diet and exercise
group, DPE); or exercise only group (E)
29–46;
54 (62%)
10 weeks Primary: Steatosis grade
(ultrasound), AST, ALT
Other: WT, BMI, WC, HC,
TC, TG, HDL, LDL, GLC,
INS, HOMA-IR, GGT,
CVE, HR
↓ steatosis* grade both groups
↓ AST* and ↓ ALT*, greatest in
DPE
↓ WT* and ↓ BMI both groups*,
greatest in DPE group (6.3% vs.
0.9% in E)
Kantartzis (2009);33
Germany
Dietary counselling consisting of 10 sessions
with dietitian and asked to perform 3 hours
moderate exercise/week (eg, walking, swimming)
19–68;
170 (41%)
9 months Primary: IHTG (MRS),
AST, ALT
Other: BMI, WC, FM, SAT,
VAT, GLC, INS, VO2 max
↓ IHTG* 35.2%; 20 of 50 NAFLD
cases were resolved at follow up
↓ AST*, and ↓ ALT*
↓ BMI*, and ↓ VAT*,
Promrat (2010);34
USA
1000–1500 kcal/day (25% fat), moderate intensity
exercise progressing to 200 min/week with
weekly (first 6 months) then biweekly health
education sessions; or basic education sessions
(every 12 weeks) on healthy eating, physical
activity and weight control
34–59;
31 (59%)
48 weeks Primary: NAS (liver
biopsy), AST, ALT
Other: WT, BMI, TG, LDL,
HDL, GLC, INS, HbA1C,
HOMA
↓ NAS*, greatest change seen in
intensive intervention(−2.4 vs. −1.4
in control)
↓ AST§, ↓ ALT*, (greatest change
seen in intensive intervention‡
See ↓ AST but no significant
difference between the two
treatment groups
↓ WT* (8.8% in intensive vs. 0.5%)
and ↓ BMI*
Rodrigues-Hernandez
(2011);35
Mexico
Low calorie (30 kcal/kg/day), low CHO (27%
protein, 28% fat, 45% CHO) plus 5 hours
exercise/week; or an isocaloric, low fat (21% fat,
25% protein, 54% CHO) with same exercise
20–65;
59 (0%)
6 months Primary: AST, ALT
Other: WT, BMI, FM, GLC,
TC, TG
↓ AST* and ↓ ALT* in both groups,
but no difference between diets.
↓ WT* (5.7% low cal, 5.5% low fat)
and ↓ BMI*
Al-Jiffri (2013);36
Saudi Arabia
1200 calories/day (15% protein, 30–35% fat,
50–55% CHO) plus aerobic exercise 30 min
3×/week
35–55
100 (100%)
3 months Primary: AST, ALT
Other: BMI, GGT,
HOMA-IR, ALP
↓ AST* and ↓ ALT* in diet plus
exercise group
↓ BMI* in AER group
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Table 3 Continued
Author (year); country Intervention
Age
range;
sample
size
(% male)
Study
duration Outcome measures
Changes to outcome measures
postintervention
Eckard (2013);37
USA
Low-fat diet (20% fat, 60% CHO, 20% protein)
with moderate exercise (20–60 min 4–7 days/
week); moderate-fat/low CHO diet (30% fat, 50%
CHO, 20% protein) with moderate exercise; or
moderate exercise only
18–70;
41 (61%)
6 months Primary: NAS (liver
biopsy), AST, ALT
Other: WT, BMI, LDL,
HDL, TG, ALP, INS, GLC
↓ NAS* in both diet and exercise
combination groups (−1.3 low fat,
−1.2 low CHO)
↓ AST§ and ↓ ALT* in all groups
No significant change in WT among
groups
Wong
(2013);38
Hong Kong
Weight loss diet supervised by dietitian weekly
(4 months) then monthly (8 months) plus
moderate-intensity aerobic exercise
30 min 3–5 days/week
42–60;
154 (46%)
1 year Primary: IHTG (H-MRS),
LS, AST, ALT
Other: WT, BMI, WC,
WHR, GLC, TC, HDL,
LDL, TG
↓ IHTG* 54%, 49 of 77 NAFLD
cases resolved (<5% IHTG at 1
year)
↓ LS*, ↓ ALT* and ↓ AST§
↓ WT* (7.9%) and ↓ BMI*
Aller (2014);39
Spain
Hypocaloric diet either high MUFA (M; 1342 kcal/
day, 21% fat of which 67% MUFA); or high PUFA
(P; 1459 kcal/day, 21% fat of which 55% PUFA);
with aerobic exercise 60 min 3×/week
32–66;
306 (28%)
3 months Primary: ALT, AST
Secondary: WT, BMI, FM,
WC, WHR, GLC, TC, LDL,
HDL, TG, INS, HOMA,
GGT
↓ ALT* and ↓ AST* in both groups
↓ WT* (4.4% M, 4.7% P) and
↓ BMI* No differences between M
and P diets
*Statistically significant.
§No statistically significant difference.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index (kg/m2); CVE, cardiovascular endurance; FM, fat mass, GGT, gamma
glutaryl transferase; GLC, glucose; HbA1c, glycosylated haemoglobin; HC, hip circumference; HDL, high-density lipoprotein; HOMA, Homeostasis Model Assessment; HOMA-IR, Homeostasis
Model Assessment-Insulin Resistance Index; HR, heart rate; IHTG, intrahepatic triglyceride; INS, insulin; LDL, low-density lipoprotein; LS, liver stiffness; MUFA, monounsaturated fat; MRS,
magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; PUFA, polyunsaturated fat; SAT, subcutaneous adipose tissue; TC, total cholesterol;
TG, triglyceride; VAT, visceral adipose tissue; VO2 max, peak oxygen consumption (mL/kg/min); WC, waist circumference; WHR, waist:hip ratio; WT, weight.
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of 10 weeks to 12 months with two exclusively studying
women35 or men.36 They all used a combination of
hypocaloric diet and regular aerobic exercise, although
protocols varied with some also assessing the beneﬁts of
resistance exercise. A 9-month study by Kantartzis et al33
used dietary counselling and moderate physical activity
recommendations, which achieved a 35.2% reduction in
liver fat (assessed by MRS), and signiﬁcant changes in
hepatic enzyme levels; resulted in 40% of participants
seeing NAFLD resolved. Similarly, in the larger cohort of
Wong et al,38 154 patients given dietary counselling ses-
sions with aerobic exercise advice over a year, there was
a considerable percent change of 54% in IHTG. Other
interventions reported the grade of NAFLD rather than
% IHTG32 34 37 but all measured an improvement in
their NAFLD grade or NAS. In the six of eight trials that
reported changes in body weight over the course of
their interventions, ﬁve studies showed weight losses of
4.4–8.8%; with Promrat et al34 showing the greatest losses
in an intensive 48-week intervention.
Quality assessment
Using the ADA quality assessment criteria (ﬁgure 2), 13
of the 24 studies were rated as positive, high-quality
trials.16–20 24 25 28 29 33 34 37 38 In eight of the trials, insufﬁ-
cient information was provided to make an informed
decision regarding the adequacy of randomisa-
tion21 22 26 27 30 32 35 36 and one trial was described as
‘semi-random’.23 One trial rated neutral provided insufﬁ-
cient evidence of group comparability,36 two neutral trials
had patients studied in two different centres20 31 and one
provided insufﬁcient information about the exercise arm
of their intervention.35 A number of the trials were rated
positive as they met criteria 2, 3, 6 and 7 of the checklist
and the majority of the checklist overall, but there were
some remaining concerns. In 10 of the trials there was
insufﬁcient description of the methods of handling with-
drawals from the trial,21–23 26 27 32 33 36 39 nine did not
provide information regarding blinding where appropri-
ate, in ﬁve there were concerns about the statistical ana-
lysis,22–24 26 33 three provided no discussion of potential
limitations23 26 36 and eight provided insufﬁcient evi-
dence regarding their funding source21–23 33 35 37 39 so
that it was not possible to reasonably conclude that the
results had not been biased as a result of the funding
source. In summary, over 50% of trials were of high
quality and those rated as neutral did have a number of
positive points.
DISCUSSION
Overall, the evidence from the interventions reviewed sug-
gests that weight loss of 5% in NAFLD or 7–10% in NASH
is beneﬁcial, and this should be achieved by a combination
of moderate dietary restriction and 30–60 min of
moderate-intensity exercise on 3–5 days per week.
Moderate-intensity exercise requires moderate effort and
noticeable acceleration of the heart rate with some
increase in rate of breathing, but the person should still be
able to hold a conversation. Moderate-intensity activities
include brisk walking, taking stairs, using a cross trainer,
gardening or vigorous housework. High-intensity exercise
Figure 2 American Dietetic
Association (ADA) Quality Criteria
Checklist carried out on the 24
eligible trials. (1) Clear Research
Question; (2) Unbiased Selection
of Participants; (3)
Randomization/Group
Comparability; (4) Description of
Withdrawals; (5) Blinding; (6)
Study Procedures Described; (7)
Clearly Defined Outcomes; (8)
Appropriate Statistical Analysis;
(9) Results Support Conclusion;
(10) Funding or Sponsorship Bias
Unlikely. To be rated positive,
each of criteria 2, 3, 6 and 7 must
be met and the majority of 10
criteria overall. Any of criteria 2, 3,
6 and 7 not being met resulted in
a neutral rating. The majority of
criteria not being met results in a
negative rating.
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requires a large effort with substantial increase in heart
rate and rapid breathing, for example, running or fast
cycling; individuals are considerably less able to hold a
conversation. The combination of diet and exercise
appears to increase the likelihood of achieving the
required weight loss and leads to greater improvements in
markers of NAFLD activity; current guidelines reﬂect
this.5 6 Interventions which improve insulin resistance also
improve markers of metabolic syndrome, and dietary
restriction and exercise have been shown to improve
insulin resistance in trials included in this
review.16 22 24 30 32 33 39 However, the relationship may be
more complex in that some individuals without insulin
resistance or obesity develop NAFLD, and while NAFLD
and metabolic syndrome have underlying pathology
strongly related to insulin resistance, the relationship may
be bi-directional.41
The results of the dietary interventions included in
this review suggest that reductions in body weight lead
to signiﬁcant improvements in NAFLD activity. NAS are
calculated based on histological grading of patients’ liver
steatosis, lobular inﬂammation and cellular ballooning.
The higher the score the greater the NAFLD severity.
Four of the trials21–24 achieved comparable weight losses
of 4% using a moderately hypocaloric diet. The study
involving the VLCD20 achieved a greater loss but these
type of diets are a unique intervention in their own
right and not intended to be a long-term lifestyle.42
Weight losses on VLCD are typically greater than the
10% recommended for maximal improvement in
NAFLD,5 6 but the risk of recurring weight gain is signiﬁ-
cant and weight loss maintenance is challenging in the
long term.43 A low carbohydrate diet may improve
NAFLD more than other forms of dietary restriction;23
however, evidence is mixed and studies comparing dif-
ferent dietary constituents showed no signiﬁcant differ-
ence between low carbohydrate and low fat diets.22 35 37
Exercise interventions on the whole resulted in more
modest beneﬁts; all of the trials achieved signiﬁcant
improvements in markers of NAFLD activity regardless
of the intervention protocol and one16 noted that 23%
of subjects experienced resolution of NAFLD. Most of
the intervention protocols in this review involved
30–60 min of exercise on 3–5 days per week. The data
demonstrate aerobic and resistance exercise are both
effective. This is an important ﬁnding because resistance
exercise is more readily available to those of the popula-
tion most at risk of NAFLD, that is, those with over-
weight/obesity. Low cardiorespiratory ﬁtness and
numerous medical conditions are often concomitant
with this population and can preclude aerobic exercise.
Therefore performing resistance exercises, relying on
body weight alone, can be effective ﬁrst steps in improv-
ing NAFLD.30 However, while statistically signiﬁcant, the
magnitude of the improvement following exercise inter-
ventions appears to be less than in dietary interventions.
Combination interventions appear to be the most
effective at improving NAFLD. Greater weight loss was
observed in the interventions reviewed, with a range of
4.4–8.8% achieved in these studies.32 34 35 38 39 The two
longest most intensive intervention trials reported the
highest losses in body weight.34 38 Al Jiffri et al36 did not
report body weight but carried out an intervention of
3 months with 100 participants, that resulted in a 15%
reduction in BMI; however reasons for this are unclear.
At 1200 kcal/day, it was one of the more hypocaloric
interventions, with an exercise protocol that was compar-
able to the other combination interventions. The
all-male cohort may be a contributing factor; men lose
more weight than women given the same physical activ-
ity intervention and are less likely to compensate for
energy expended during exercise by increasing energy
intake45 46 which may result in greater adherence to the
dietary component of the intervention. However, the
improvement in transaminases that they demonstrated is
similar to those in studies achieving lesser weight reduc-
tions and 15% BMI losses are unlikely to be achievable
in the clinical setting. All of the combination interven-
tions noted a signiﬁcant improvement in markers of
NAFLD; while the interventions were varied in the
details, they were broadly similar, measuring improve-
ments in transaminases comparable with those achieved
in the weight loss trials. However, transaminase levels do
not provide as much information about NAFLD activity
as imaging and histology, and are found to be normal in
80% of those with clinically diagnosed NAFLD.47
Evidence that weight loss by energy restriction and
exercise leads to an improvement in NAFLD, as dis-
cussed here, is consistent in that each of the trials
included achieved a signiﬁcant reduction in one or
more markers of NAFLD activity. However, further clari-
ﬁcation is needed; trials were varied in size and dur-
ation, and the heterogeneity of both these and the
intervention designs produced equally diverse results.
Such diversity limits the extent to which reliable conclu-
sions can be drawn; nevertheless, evidence-based recom-
mendations regarding weight loss and exercise for the
management of NAFLD can still be made while acknow-
ledging that some aspects currently remain incompletely
understood. The ability to assess patients with NAFLD in
the trial setting is enhanced with more advanced
imaging techniques and larger RCTs of longer duration
are needed to further investigate the effects of lifestyle
on NAFLD.
The mechanisms by which dietary restriction and
increased exercise improve NAFLD are not fully under-
stood. Weight loss and exercise are already known to
improve other components of metabolic syndrome,48 so
the ﬁnding that they also improve the hepatic compo-
nent of this multiorgan disease is not entirely unex-
pected. Improvements in NAFLD without weight loss
may be due to a change of body composition. During
interventions involving exercise, fat mass will be lost and
muscle mass will be gained, and these opposing changes
can result in no overall effect on total body weight. It is
possible that it is the fat loss which is important as
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systemic fat loss is associated with a reduction in
IHTG,33 or increased metabolic activity of new muscle
mass confers beneﬁts including increased resting meta-
bolic rate.49 An alternative hypothesis is that NAFLD
and obesity are inﬂammatory metabolic states and it is
the anti-inﬂammatory effects of the exercise that lead to
the improvements seen.9 50
In conclusion, this review has found that interventions
involving a combination of dietary restriction and exer-
cise, associated with weight loss, are effective in reducing
NAFLD activity, in many cases leading to resolution of
the condition. Patients with NAFLD should be advised to
aim to lose 5–10% of their total body weight by eating a
modestly hypocaloric (−500 kcal per day) diet and
engaging in regular exercise for 30–60 min on 3–5 days
per week. Dietary composition is probably less important
than total energy intake, although a low-carbohydrate
diet may be slightly more effective than the alternatives if
it is acceptable to the individual. Aerobic and resistance
exercise both appear to be equally effective, but less so
alone without dietary intervention. Achieving this
amount of weight loss is challenging in the existing obe-
sogenic environment and clinical intervention is needed,
either in a tier 3 multidisciplinary weight management
clinic or via bariatric surgery, which is beyond the scope
of this review. Tier 3 clinics are currently underdeveloped
to meet existing need and an increase in this type of
service is desirable, to support patients and reduce
NAFLD progression.
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